Skip to main content

Advertisement

SpringerLink
Log in

Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Hepatocellular carcinoma (HCC) is often diagnosed at advanced stage where effective therapies are lacking. Identification of new scoring system is needed to discriminate HCC patients from those with chronic liver disease. Based on the link between vascular endothelial growth factor (VEGF) and HCC progression, we aimed to develop a novel score based on combination of VEGF and routine laboratory tests for early prediction of HCC. VEGF was assayed for HCC group (123), liver cirrhosis group (210), and control group (50) by enzyme-linked immunosorbent assay (ELISA). Data from all groups were retrospectively analyzed including α-fetoprotein (AFP), international normalized ratio (INR), albumin and platelet count, transaminases, and age. Areas under receiving operating curve (ROC) were used to develop the score. A novel index named hepatocellular carcinoma-vascular endothelial growth factor score (HCC-VEGF score) = 1.26 (numerical constant + 0.05 × AFP (U l−1) + 0.038 × VEGF (ng ml−1) + 0.004 × INR − 1.02 × albumin (g l−1) − 0.002 × platelet count × 109 l − 1 was developed. HCC-VEGF score produce area under ROC curve of 0.98 for discriminating HCC patients from liver cirrhosis with sensitivity of 91 % and specificity of 82 % at cutoff 4.4 (i.e., less than 4.4 considered cirrhosis and greater than 4.4 considered HCC). Hepatocellular carcinoma-VEGF score could replace AFP in HCC screening and follow up of cirrhotic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nafee AM, Pasha HF, Abd El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem. 2012;45:1070–4.

    Article  CAS  PubMed  Google Scholar 

  2. Welzel TM, Graubard BI, Zeuzem S, El–Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15:297–306.

    Article  PubMed  Google Scholar 

  4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  5. Chen L, Ho DW, Lee NP, et al. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518–25.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Kew MC. Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World J Hepatol. 2012;4:99–104.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33:1013–1021.

    Google Scholar 

  9. Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 1999;30:1179–86.

    Article  CAS  PubMed  Google Scholar 

  10. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16:552–7.

    Article  PubMed  Google Scholar 

  11. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–53.

    CAS  PubMed  Google Scholar 

  12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

    Article  CAS  PubMed  Google Scholar 

  13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.

    Article  PubMed  Google Scholar 

  14. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 2004;11:383–93.

    Article  CAS  PubMed  Google Scholar 

  15. Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007;383:147–52.

    Article  CAS  PubMed  Google Scholar 

  16. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2009;124:690–7.

    Article  CAS  PubMed  Google Scholar 

  17. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–10.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009;29:478–80.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett. 2002;179:95–101.

    Article  CAS  PubMed  Google Scholar 

  20. El-Mezayen HA, el Toson SA, Darwish H, El-Badry E. Discriminant function based on parameters of hyaluronic acid metabolism and nitric oxide to differentiate metastatic from non-metastatic colorectal cancer patients. Tumour Biol. 2012;33:995–1004.

    Article  CAS  PubMed  Google Scholar 

  21. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845–8.

    Article  CAS  PubMed  Google Scholar 

  22. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23:455–64.

    Article  CAS  PubMed  Google Scholar 

  23. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996;56:3004–9.

    CAS  PubMed  Google Scholar 

  24. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.

    Article  CAS  PubMed  Google Scholar 

  25. El-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11:5193–8.

    PubMed Central  PubMed  Google Scholar 

  26. Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Gastroenterology. 1996;110:184–92.

    Article  CAS  PubMed  Google Scholar 

  27. Kojiro M. Pathological evolution of early hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:43–7.

    Article  CAS  PubMed  Google Scholar 

  28. Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology. 2004;40:1465–73.

    Article  PubMed  Google Scholar 

  29. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127:S113–9.

    Article  CAS  PubMed  Google Scholar 

  30. Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Fliser D, Zurbruggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55:629–34.

    Article  CAS  PubMed  Google Scholar 

  32. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002;106:2919–24.

    Article  CAS  PubMed  Google Scholar 

  33. Masuzaki R, Tateishi R, Yoshida H, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42:839–43.

    Article  PubMed  Google Scholar 

  34. Attallah AM, El-Far M, Abdel Malak CA, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2011;412:2310–5.

    Article  CAS  PubMed  Google Scholar 

  35. Dai CY, Ho CK, Huang JF, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2009;52:160–166.

    Google Scholar 

  36. Saad WE, Darwish WM, Davies MG, et al. Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical analysis and clinical outcome. AJR Am J Roentgenol. 2013;200:210–8.

    Article  PubMed  Google Scholar 

  37. Daskalow K, Rohwer N, Raskopf E, et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 2010;88:817–27.

    Article  CAS  Google Scholar 

  38. Tangkijvanich P, Tosukhowong P, Bunyongyod P, et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30:110–4.

    CAS  PubMed  Google Scholar 

  39. Bachtiar I, Santoso JM, Atmanegara B, et al. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta. 2009;399:97–101.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr Mohamed El-Laban at Internal Medicine Department, Damietta General Hospital, Damietta, Egypt for providing us with the samples needed in this study.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Chemistry Department, Helwan University, Cairo, Egypt

    Hatem A. El-mezayen

  2. Medical Oncology Department, Damietta Cancer Institute, Damietta, Egypt

    Hossam Darwish

Authors
  1. Hatem A. El-mezayen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hossam Darwish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hatem A. El-mezayen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-mezayen, H.A., Darwish, H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumor Biol. 35, 6501–6509 (2014). https://doi.org/10.1007/s13277-014-1858-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1858-4

Keywords

Search

Navigation